Latest Vestal Point Capital, LP Stock Portfolio

$3.58Billion– No. of Holdings #90

Vestal Point Capital, LP Performance:

2026 Q1: 0.96%YTD: 0.96%2025: 15.37%

Performance for 2026 Q1 is 0.96%, and YTD is 0.96%, and 2025 is 15.37%.

About Vestal Point Capital, LP and 13F Hedge Fund Stock Holdings

Vestal Point Capital, LP is a hedge fund based in New York, NY. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Vestal Point Capital, LP reported an equity portfolio of $3.6 Billions as of 31 Mar, 2026.

The top stock holdings of Vestal Point Capital, LP are RVMD, BMRN, . The fund has invested 6.5% of it's portfolio in REVOLUTION MEDICINES INC and 5.7% of portfolio in BIOMARIN PHARMACEUTICAL INC.

The fund managers got completely rid off ARCELLX INC (ACLX), DEXCOM INC (DXCM) and MERCK & CO INC (MRK) stocks. They significantly reduced their stock positions in TYRA BIOSCIENCES INC (TYRA), TERNS PHARMACEUTICALS INC (TERN) and GERON CORP (GERN). Vestal Point Capital, LP opened new stock positions in NEUROCRINE BIOSCIENCES INC (NBIX), SANOFI SA (SNY) and BOSTON SCIENTIFIC CORP (BSX). The fund showed a lot of confidence in some stocks as they added substantially to DYNE THERAPEUTICS INC (DYN), REPLIGEN CORP (RGEN) and NUVALENT INC (NUVL).

Vestal Point Capital, LP Equity Portfolio Value

Last Reported on: 15 May, 2026

Vestal Point Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Vestal Point Capital, LP made a return of 0.96% in the last quarter. In trailing 12 months, it's portfolio return was 35.73%.

Performance
S&P 500

New Buys

Ticker	$ Bought
neurocrine biosciences inc	164,675,000
sanofi sa	67,452,000
boston scientific corp	50,200,000
cogent biosciences inc	47,376,900
united therapeutics corp	44,473,500
bright minds biosciences inc	35,924,500
protagonist therapeutics inc	34,377,200
regeneron pharmaceuticals inc	30,905,600

New stocks bought by Vestal Point Capital, LP

Additions

Ticker	% Inc.
dyne therapeutics inc	3,233
repligen corp	1,014
nuvalent inc	947
revolution medicines inc	705
immunocore holdings plc	372
monte rosa therapeutics inc	364
bristol-myers squibb co	300
denali therapeutics inc	281

Additions to existing portfolio by Vestal Point Capital, LP

Reductions

Ticker	% Reduced
tyra biosciences inc	-97.77
terns pharmaceuticals inc	-77.78
geron corp	-77.56
olema pharmaceuticals inc	-74.03
novocure ltd	-52.38
globus medical inc	-52.12
alcon ag	-27.6
nyxoah sa	-21.53

Vestal Point Capital, LP reduced stake in above stock

Sold off

Ticker	$ Sold
day one biopharmaceuticals inc	-48,464,000
arcellx inc	-190,710,000
fate therapeutics inc	-1,694,980
rezolute inc	-3,978,960
dexcom inc	-84,621,800
black diamond therapeutics inc	-2,114,100
zymeworks inc	-22,775,400
merck & co inc	-81,576,500

Vestal Point Capital, LP got rid off the above stocks

Sector Distribution

Vestal Point Capital, LP has about 65.7% of it's holdings in Healthcare sector.

Healthcare
Others

Sector	%
Healthcare	65.7
Others	33.9

Market Cap. Distribution

Vestal Point Capital, LP has about 26% of it's portfolio invested in the large-cap and mega-cap stocks.

UNALLOCATED
LARGE-CAP
MID-CAP
SMALL-CAP

Category	%
UNALLOCATED	33.9
LARGE-CAP	26
MID-CAP	22.6
SMALL-CAP	16.3

Stocks belong to which Index?

About 41.7% of the stocks held by Vestal Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

Others
RUSSELL 2000
S&P 500

Index	%
Others	58.3
RUSSELL 2000	35.6
S&P 500	6.1

Top 5 Winners (%)		%
	enliven therapeutics inc	142.8 %
MGNX	macrogenics inc	79.5 %
	crescent biopharma inc	54.9 %
	tectonic therapeutic inc	48.2 %
TENX	tenax therapeutics inc	31.2 %

Top 5 Winners ($)		$
	enliven therapeutics inc	84.3 M
TERN	terns pharmaceuticals inc	33.9 M
RVMD	revolution medicines inc	23.5 M
TYRA	tyra biosciences inc	14.9 M
	bicara therapeutics inc	13.8 M

Top 5 Losers (%)		%
	beta bionics inc	-56.5 %
	lexeo therapeutics inc	-42.2 %
PASG	passage bio inc	-33.5 %
	nyxoah sa	-32.6 %
RGNX	regenxbio inc	-32.0 %

Top 5 Losers ($)		$
	abivax sa	-40.0 M
	beta bionics inc	-28.7 M
RGEN	repligen corp	-23.2 M
NRIX	nurix therapeutics inc	-19.4 M
	lexeo therapeutics inc	-18.8 M

Vestal Point Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Vestal Point Capital, LP

Vestal Point Capital, LP has 90 stocks in it's portfolio. About 40.4% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for Vestal Point Capital, LP last quarter.

Last Reported on: 15 May, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABSI	absci corp	0.02	232,219	696,657	new

ABT	abbott laboratories	0.00	0.00	0.00	sold off	-100

ACLX	arcellx inc	0.00	0.00	0.00	sold off	-100

AGIO	agios pharmaceuticals inc	0.43	450,000	15,223,500	added	38.46

ALC	alcon ag	1.69	800,000	60,280,000	reduced	-27.6

ALEC	alector inc	0.00	0.00	0.00	sold off	-100

APRE	aprea therapeutics inc	0.01	350,000	267,015	new

ARVN	arvinas inc	0.27	905,465	9,597,930	new

ARWR	arrowhead pharmaceuticals inc	3.99	2,275,000	142,642,000	added	152

ASND	ascendis pharma a/s	2.40	375,000	85,773,800	added	114

AXSM	axsome therapeutics inc	0.00	0.00	0.00	sold off	-100

BCRX	biocryst pharmaceuticals inc	1.87	7,025,000	66,878,000	added	212

BDTX	black diamond therapeutics inc	0.00	0.00	0.00	sold off	-100

BMRN	biomarin pharmaceutical inc	5.65	3,575,000	201,952,000	added	19.17

BMY	bristol-myers squibb co	1.70	1,000,000	60,650,000	added	300

BSX	boston scientific corp	1.40	800,000	50,200,000	new

CADL	candel therapeutics inc	0.15	1,125,000	5,512,500	new

CLDX	celldex therapeutics inc	1.09	1,224,160	38,830,500	added	5.08

COGT	cogent biosciences inc	1.32	1,230,890	47,376,900	new

CYTK	cytokinetics inc	0.55	300,000	19,773,000	new